Shearman, 1963 - Google Patents
Excretion of ovarian steroids in patients treated with an “ovulation inhibitor”Shearman, 1963
- Document ID
- 796051352822677598
- Author
- Shearman R
- Publication year
- Publication venue
- Obstetrical & Gynecological Survey
External Links
Snippet
Each tablet of anovlar contains norethisterone acetate 4 mg. and ethinyl estradiol 0.05 mg. In all treated cycles medication started on the fifth day and continued daily for 20 days. Assays of estrogens by the Brown method and pregnanediol by the Klopper method were …
- 230000036826 Excretion 0 title abstract description 9
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S514/00—Drug, bio-affecting and body treating compositions
- Y10S514/841—Contraceptive
- Y10S514/843—Female mammal
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S514/00—Drug, bio-affecting and body treating compositions
- Y10S514/899—Menstrual disorder
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mishell Jr et al. | Serum estradiol in women ingesting combination oral contraceptive steroids | |
| Brown et al. | The effect of norethisterone and its acetate on ovarian and pituitary function during the menstrual cycle | |
| GORE et al. | Estrogen-induced human luteolysis | |
| SOHVAL et al. | The influence of cortisone and adrenocorticotropin on urinary gonadotropin excretion | |
| Klein et al. | Gonadotropin, prolactin, and steroid hormone levels after discontinuation of oral contraceptives | |
| Tyson et al. | Inhibition of cyclic gonadotropin secretion by endogenous human prolactin | |
| Vorherr | Contraception after abortion and post partum: An evaluation of risks and benefits of oral contraceptives with emphasis on the relation of female sex hormones to thromboembolism and genital and breast cancer | |
| Shearman | Excretion of ovarian steroids in patients treated with an “ovulation inhibitor” | |
| Drill | Endocrine properties and long-term safety of oral contraceptives | |
| Kind et al. | Anti-ovulatory activity of subcutaneously injected steroids in the adult oestrus rabbit | |
| Greenblatt et al. | Delay of menstruation with norethindrone, an orally given progestational compound | |
| Zanartu | Long-term contraceptive effect of injectable progestogens: inhibition and reestabilishment of fertility | |
| Twombly et al. | Endometrial cancer, obesity, and estrogenic excretion in women | |
| Drill | History of the first oral contraceptive | |
| Kurzrok | The prospects for hormonal sterilization | |
| Jeppsson et al. | Basal and LRH-stimulated secretion of FSH during early pregnancy | |
| Barnes et al. | Cyproterone acetate: a study involving two volunteers with idiopathic hirsutism | |
| Mishell Jr et al. | Effect of varying dosages of ethynodiol diacetate upon serum luteinizing hormone | |
| Kaiser et al. | Sequential and Combined Therapy in Oral Contraception Mode of Action and Efficiency | |
| Tredway et al. | Effect of a once weekly oral contraceptive upon gonadotrophin and gonadal steroid levels | |
| Cohen et al. | Further studies on pituitary and ovarian function in women receiving hormonal contraception | |
| Bonnar | Post-pill Amenorrheea [Abridged] Pituitary and ovarian function in post-pill amenorrhea | |
| Schwarz et al. | Unsustained central sexual precocity in girls | |
| Barfield et al. | The treatment of functional amenorrhea | |
| Lunenfeld | THE OVARIAN RESPONSE TO EXOGENOUS HUMAN GONADO-TROPINS ALONE AND DURING SIMULTANEOUS ADMINISTRATION OF PROGESTOGENS |